EC Approves Second Indication of Sarclisa® for Relapsed Multiple Myeloma
The European Commission (EC) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult
Read moreThe European Commission (EC) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult
Read moreGSK and Vir Biotechnology have announced that the EMA has started a review of the dual-action monoclonal Antibody VIR-7831 for
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreFrench pharma giant Sanofi is set to acquire Tidal Therapeutics for $470m, adding the biotech’s novel mRNA-based research platform with
Read moreBristol Myers Squibb announced positive results from a Phase 3 Trial, which showed that neoadjuvant treatment with three cycles of
Read moreExscientia, a leading artificial intelligence (AI) driven pharmatech company based in Oxford, England, announced that the first AI-designed molecule for
Read moreTeva Pharmaceuticals Europe reported that Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/fluticasone propionate, 12.75/100 and 12.75/202 micrograms administered
Read moreThe Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Panacea Biotec, India’s largest vaccine and pharmaceutical manufacturer, have
Read moreContract Development and Manufacturing Organization Celonic and German biopharmaceutical company CureVac have entered into an agreement to manufacture 100 Million
Read moreJohnson & Johnson has started vaccinating teens aged 12 to 17 in the ongoing Phase 2a clinical trial for its
Read more